Additional Preclinical
Promotions Round Out Scientific Leadership
SAN
DIEGO, Nov. 29, 2022 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
the appointments of Rekha Garg,
M.D., M.S., to Senior Vice President, Clinical Development and
Regulatory, and Claire Padgett,
Ph.D. to Senior Vice President, Clinical Operations. The company
also announced the promotion of Morgan
Carlson, Ph.D., to Vice President, Biology and Edmund Lee, Ph.D., to Vice President,
Translational Medicine. Lastly, the Company announced, Denis Drygin, Ph.D., has stepped down from his
role as Chief Scientific Officer to pursue other opportunities.
![Regulus Therapeutics Inc. Logo Regulus Therapeutics Inc. Logo](https://mma.prnewswire.com/media/370141/regulus_logo_finalnew_Logo.jpg)
"We are very pleased to announce the appointment of these two
industry veterans to focus on advancing RGLS8429 through clinical
trials for the benefit of patients with ADPKD," said Jay
Hagan, President and Chief Executive Officer of Regulus
Therapeutics. "Both Drs. Garg and Padgett have been working with
the Company as consultants moving the Phase 1 ADPKD program forward
and we are happy to welcome them as employees to the Regulus
team. Additionally, the promotions of Dr. Lee and Dr. Carlson
to the newly created roles of Vice President, Translational
Medicine and Vice President, Biology are in recognition of their
accomplishments in the development of our biomarker strategy for
our ADPKD program as well as the effective leadership of our
earlier stage research efforts. We would also like to express our
gratitude to Denis, thank him for his many contributions and wish
him the best in the next phase of his career."
Dr. Garg is a physician executive with over 20 years of
experience in leadership roles in the biopharma industry, across
multiple therapeutic areas including kidney diseases. Before
joining Regulus, she was Senior Vice President, Regulatory Affairs
and Safety, at Sanifit Therapeutics. Prior to that, she was Vice
President at Infinity Pharmaceuticals and served in multiple
leadership roles in clinical development focused on regulatory
affairs and risk management at Amgen and Eli Lilly. Prior to
joining the pharmaceutical industry, she held a similar role the
National Heart, Lung, and Blood Institute. Dr. Garg received her BA
in Biology from Oberlin College, her
M.D. from the Medical College of Ohio
and completed her residency at the University
of Maryland School of Medicine where she also received an
M.S. in Epidemiology.
Dr. Padgett has more than 25 years of experience in clinical and
development operations, with experience in these functions accrued
at multiple biotech companies including Sanifit Therapeutics, a
company focused on the Phase 3 clinical development of SNF472 in
chronic kidney disease. Previously she held similar roles at Mirati
Therapeutics, Mast Therapeutics, and Cylene Pharmaceuticals. She
earned an MBA from Seton Hall
University and holds a Ph.D. in organizational management
and leadership from Capella
University.
Dr. Lee joined Regulus in 2013 from Hoffmann-La Roche and
Millennium Pharmaceuticals (now Takeda Oncology), where he
participated in the discovery of the proteosome inhibitor ixazomib
(MLN9708) for the treatment of multiple myeloma. Edmund has led
numerous discovery and translational research programs at Regulus,
including most recently the first anti-miR-17 oligonucleotide
(RGLS4326), as well as the next-generation anti-miR-17 (RGLS8429)
for the potential treatment of ADPKD. Edmund received his Ph.D. in
cell and molecular biology from the University
of Notre Dame and completed his postdoctoral training at the
Fred Hutchinson Cancer Research Center.
Dr. Carlson joined Regulus in 2020. He was previously a senior
investigator at Novartis, and before that, an assistant professor
of genetics and developmental biology at the University of Connecticut School of Medicine and
Stem Cell Institute, where his research laboratory focused on
biological aging and tissue regeneration to drive the discovery of
novel mechanisms and therapeutics for treating musculoskeletal
degenerative disease. Dr. Carlson earned a joint Ph.D. in
bioengineering from University of California,
San Francisco and Berkeley,
and was a postdoctoral research fellow at Children's Hospital of
Oakland Research Institute and University of
California, Berkeley.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a
biopharmaceutical company focused on the discovery and development
of innovative medicines targeting microRNAs. Regulus has leveraged
its oligonucleotide drug discovery and development expertise to
develop a pipeline complemented by a rich intellectual property
estate in the microRNA field. Regulus maintains its corporate
headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's RGLS8429
program, including the expected timing and future occurrence of
other preclinical and clinical activities. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
in the endeavor of building a business around such drugs, and the
risk additional toxicology data may be negative. In addition, while
Regulus expects the COVID-19 pandemic to adversely affect its
business operations and financial results, the extent of the impact
on Regulus' ability to achieve its preclinical and clinical
development objectives and the value of and market for its common
stock, will depend on future developments that are highly uncertain
and cannot be predicted with confidence at this time, such as the
ultimate duration of the pandemic, travel restrictions,
quarantines, social distancing and business closure requirements in
the U.S. and in other countries, and the effectiveness of actions
taken globally to contain and treat the disease. These and other
risks are described in additional detail in Regulus' filings with
the Securities and Exchange Commission, including under the "Risk
Factors" heading of Regulus most recently quarterly report on Form
10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Regulus
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-appointments-of-industry-veterans-drs-rekha-garg-and-claire-padgett-to-lead-clinical-development-regulatory-and-clinical-operations-301688364.html
SOURCE Regulus Therapeutics Inc.